Trial Profile
Phase 1b Open-label, Single Arm, Cohort Dose Escalation Study Evaluating the Safety, Tolerability, and Feasibility of Intervention With AT-100 (rhSP-D) in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection or Respiratory Failure Secondary to Severe Community Acquired Pneumonia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Zelpultide alfa (Primary)
- Indications COVID 2019 infections; Respiratory insufficiency
- Focus Adverse reactions
- Sponsors Airway Therapeutics
- 07 Jul 2023 Status changed from recruiting to discontinued because study goals reached.
- 12 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.
- 12 Jan 2023 Planned primary completion date changed from 1 Oct 2022 to 1 May 2023.